Bench-to-bedside review: Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unit by Skrupky, Lee P et al.
Available online http://ccforum.com/content/13/5/222
Page 1 of 8
(page number not for citation purposes)
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) displays a
remarkable array of resistance and virulence factors, which have
contributed to its prominent role in infections of the critically ill. We
are beginning to understand the function and regulation of some of
these factors and efforts are ongoing to better characterize the
complex interplay between the microorganism and host response.
It is important that clinicians recognize the changing resistance
patterns and epidemiology of Staphylococcus  spp., as these
factors may impact patient outcomes. Community-associated
MRSA clones have emerged as an increasingly important subset of
Staphyloccocus aureus and MRSA can no longer be considered
as solely a nosocomial pathogen. When initiating empiric anti-
biotics, it is of vital importance that this therapy be timely and
appropriate, as delays in treatment are associated with adverse
outcomes. Although vancomycin has long been considered a first-
line therapy for serious MRSA infections, multiple concerns with
this agent have opened the door for existing and investigational
agents demonstrating efficacy in this role.
Methicillin-resistant Staphylococcus aureus (MRSA) has
proven to be a prominent pathogen in the ICU setting capable
of causing a variety of severe infections. In the face of
increasing antibiotic pressure, increased resistance and
virulence has been noted to occur and recent research is
helping us to better understand the complex interplay between
the invading microorganism and the ensuing host immune
response. This review will focus on the resistance mechanisms
and virulence factors employed by MRSA, their associated
impact on patient outcomes and current treatment options.
Antibiotic resistance
Methicillin-resistance in Staphylococcus species is encoded
via the mecA gene, which results in production of penicillin-
binding protein (PBP)2A, a penicillin binding protein with
reduced affinity for β-lactams [1]. mec is part of a larger
genomic element termed the Staphylococcal chromosomal
cassette (SCCmec), which contains genes mediating anti-
biotic resistance. Up to eight types of SCCmec have now
been reported in the literature [2] and the differences between
these SCCmec types account for the primary differences
between various MRSA clones. For example, SCCmec I, II,
and III are larger and more difficult to mobilize and are most
frequently present in hospital acquired (HA-MRSA) clones
(USA 100 and 200). SCCmec IV is a smaller, easier to
mobilize genetic element that is frequently present in
community-associated MRSA (CA-MRSA; clones USA 300
and 400) [3]. It has been observed that CA-MRSA is
effectively integrating into the health care environment and it
is therefore increasingly less reliable to make this differen-
tiation on the basis of acquisition location [4-7]. HA-MRSA
and CA-MRSA clones are noted to display different resis-
tance patterns as a result of their unique genetic elements.
Compared with HA-MRSA, CA-MRSA isolates are more likely
to be susceptible to non-β-lactam antibiotics, including tri-
methoprim-sulfamethoxazole (TMP-SMX), clindamycin, fluoro-
quinolones, gentamicin, erythromycin, and tetracyclines with
geographic variability [7-9].
Increasing attention is being paid to the issue of reduced
susceptibility and resistance of MRSA to vancomycin.
Although vancomycin has long been considered a reliable
agent for treatment of MRSA infections, isolates with
intermediate (VISA) and full (VRSA) levels of resistance have
been reported. The Clinical and Laboratory Standards
Institute vancomycin minimum inhibitory concentration (MIC)
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breakpoints for MRSA were last updated in 2006 and
resulted in a lowering of the breakpoints as follows: suscep-
tible, ≤2 μg/ml; intermediate, 4 to 8 μg/ml; resistant, ≥16 μg/ml.
Vancomycin exerts its antibiotic activity by binding to the D-
alanyl-D-alanine portion of cell wall precursors, which
subsequently inhibits peptidoglycan polymerization and trans-
peptidation. High-level resistance is mediated via the vanA
gene, which results in production of cell wall precursors (D-
Ala-D-lac or D-Ala-D-Ser) with reduced affinity for vanco-
mycin [10]. Intermediate level resistance (VISA) is believed to
be preceded by the development of heteroresistant vanco-
mycin intermediate S. aureus (hVISA) [11]. Heteroresistance
is the presence of resistant subpopulations within a popu-
lation of bacteria determined to be susceptible to the
antibiotic tested. It is thought that exposure of such a
heteroresistant MRSA population to low concentrations of
vancomycin may kill the fully susceptible subpopulations and
select for the resistant subpopulations. The mechanisms of
heteroresistance are not fully elucidated, but are
hypothesized to be due to a thickened cell wall and increased
production of false binding sites [11]. The accessory gene
regulator (agr; discussed in detail below) type and function-
ality may also play a role in the development of this type of
resistance [12].
Reduced susceptibility to glycopeptides may also impact the
susceptibility of MRSA to daptomycin. Several reports have
found hVISA and VISA isolates to display resistance to
daptomycin [13-15]. Daptomycin is a cyclic lipopetide that
works by binding to the cell membrane to subsequently
cause destabilization resulting in bactericidal activity. It is
hypothesized that the thickened cell wall noted to occur in
MRSA isolates with intermediate-level vancomycin resistance
may result in sequestration of daptomycin. Additionally,
reduced susceptibility has been documented to develop
while on prolonged daptomycin therapy [16,17].
Linezolid is a synthetic oxazolidinone that inhibits the initiation
of protein synthesis by binding to the 23s ribosomal RNA and
thereby preventing formation of the 70s initiation complex.
Although linezolid has generally remained a reliable antibiotic
for MRSA infections, several occurrences of resistance have
been observed [18,19]. The first report of resistance [18]
from a clinical isolate was reported in 2001, about 15 months
after the drug was introduced to the market. Upon analysis,
the organism was found to have mutations in the DNA
encoding a portion of the 23s ribosomal RNA (rRNA).
Linezolid resistance has been identified more commonly
among  Staphylococcus epidermidis and  Enterococcus
species, but the possibility of linezolid resistance among
MRSA should be kept in mind.
In vitro studies have reported tigecycline to be highly active
against MRSA isolates that have been tested. No reports of
resistance to clinical isolates have been reported to our
knowledge, but the use of this agent for serious MRSA
infections has been very limited. Quinupristin/dalfopristin has
similarly been shown to be highly active in vitro against
MRSA, but clinical isolates with resistance have been
reported [20] and the use of this agent for serious MRSA
infections has also been limited.
Virulence factors for MRSA
Virulence factors play an important role in determining the
pathogenesis of MRSA infections. Colonization by MRSA is
enhanced by biofilm formation, antiphagocytocic micro-
capsules, and surface adhesions [21]. Once an inoculum is
established,  S. aureus can produce a variety of virulence
factors to mediate disease, including exoenzymes and toxins.
Exoenzymes include proteases, lipases and hyaluronidases,
which can cause tissue destruction and may facilitate spread
of infection. The toxins that can be produced are numerous
and include hemolysins, leukocidins, exfoliative toxins,
Panton-Valentine leukocidin (PVL) toxin, toxic shock
syndrome toxin (TSST-1), enterotoxins, and α-toxin [21].
S. aureus also has a multitude of mechanisms to further elude
and modulate the host immune response. Specific examples
include inhibition of neutrophil chemotaxis via a secreted
protein called chemotaxis inhibitory protein of staphylococci
(CHIPS), resistance to phagocytosis via surface proteins (for
example, protein A and clumping factor A (ClfA)), inactivation
of complement via Staphylococcus complement inhibitor
(SCIN), and production of proteins that confer resistance to
lysozyme (for example, O-acetyltransferase) and antimicrobial
peptides (for example, modified Dlt proteins and MprF
protein) [22].
Various toxins have been associated with different clinical
scenarios and clinical presentations [21]. For example, α-toxin,
enterotoxin, and TSST-1 are believed to lead to extensive
cytokine production and a resulting systemic inflammatory
response. Epidermolytic toxins A and B cause the
manifestations of Staphylococcal scalded skin syndrome. PVL
is most frequently associated with CA-MRSA and may play an
important role in cavitary pneumonia and necrotizing skin and
soft tissue infections, as discussed in the following section.
Expression of virulence factors is largely controlled by the agr
[23]. Polymorphisms in agr account for the now five different
types that have been identified. HA-MRSA isolates are most
frequently agr group II, whereas CA-MRSA isolates are most
frequently agr groups I and III. Another difference is that agr is
functional in a majority of CA-MRSA isolates whereas agr
may be dysfunctional in about half of HA-MRSA isolates [24].
When agr is active it generally results in upregulation of
secreted factors and downregulation of cell surface virulence
factors. This pattern of expression has been noted to occur
during the stationary growth phase when studied in vitro and
in animal models. During an exponential growth phase,
upregulation of cell surface factors is increased and
production of secreted factors is decreased. A recent study[25] sought to examine virulence gene expression in humans
by measuring transcript levels of virulence genes in samples
taken directly from children with active CA-MRSA skin and
soft tissue infections (superficial and invasive abscesses).
This analysis showed that genes encoding secretory toxins,
including PVL, were highly expressed during both superficial
and invasive CA-MRSA infections whereas surface asso-
ciated protein A (encoded by spa) was only associated with
invasive disease. It was also demonstrated that the virulence
gene expression profiles measured from in vivo samples
differed from those observed when the clinical isolates were
exposed to purified neutrophils in vitro. This study therefore
found some differences between in vitro and animal models
when compared to this in vivo assessment and supports the
hypothesis that the course of an MRSA infection can be
altered in recognition of host-specific signals.
The changing epidemiology and impact of
resistance and virulence on outcomes
The era of MRSA being exclusively a nosocomial pathogen is
quickly fading. An epidemiologic study conducted in
metropolitan areas throughout the United States found only
27% of MRSA sterile-site infections are of nosocomial origin
[26]. Taking a closer look, of the 63% of patients presenting
from the ‘community’, the majority had recent healthcare
exposures, including hospitalization in the previous 12
months, residence in a nursing care facility, chronic dialysis,
and presence of an invasive device at the time of admission.
This group of patients deemed to have ‘healthcare-asso-
ciated, community-onset’ infection most often harbor strains
of MRSA associated with the hospital setting; however,
crossover of the CA-MRSA clone into these patients is
occurring in many healthcare centers [4-7].
Numerous studies have evaluated the impact methicillin
resistance has on the outcome of patients infected with S.
aureus. A meta-analysis of 31 S. aureus bacteremia studies
found a significant increase in mortality associated with
MRSA bacteremia compared to methicillin-susceptible S.
aureus (MSSA) bacteremia (pooled odds ratio 1.93, 95%
confidence interval 1.54 to 2.42; P < 0.001). This finding
remained evident when the analysis was limited to studies
that were adjusted for potential confounding factors, most
notably severity of illness [27]. Since this publication, several
other investigations comparing MRSA and MSSA
bacteremia have yielded similar results [28]. The higher
attributable mortality associated with MRSA could be
explained, in part, by significant delays in the administration
of an antibiotic with anti-MRSA activity, particularly in
patients presenting from the community. A single-center
cohort study found only 22% of MRSA sterile-site infections
cultured within the first 48 hours of hospital admission
received an anti-MRSA antibiotic within the first 24 hours of
culture collection, a factor that was independently
associated with hospital mortality [29], and a significant
contributor to hospital length of stay and costs [30].
In the majority of hospitals throughout the world, the antibiotic
of choice for empiric therapy of suspected MRSA infection is
vancomycin. However, just as the era of MRSA occurring only
in the hospital setting has ended, so too might the automatic,
empiric use of vancomycin in these situations. Increasingly it
is being reported that MRSA infections with vancomycin
MICs in the higher end of the ‘susceptible’ range (1.5 to
2 mcg/ml) may be associated with higher rates of treatment
failure compared to isolates with a MIC of 1 mcg/ml or less
[31]. Additionally, a cohort analysis of MRSA bacteremia
found vancomycin therapy in isolates with an MIC of
2 mcg/ml was associated with a 6.39-fold increase in the
odds of hospital mortality [32].
As the predominant genetic background of MRSA is
transitioning from that of the hospital to community architec-
ture (for example, clones USA 100 to USA 300) in
hospitalized patients, so too might the severity of infection.
Because of its epidemiologic association with CA-MRSA and
severe, necrotizing pneumonia, PVL has gained much
attention as an important virulence factor. However, the
extent of its role in pathogenesis is a matter of significant
debate and it is likely that other factors, including expression
of adhesion proteins such as staphylococcal protein A, as
well as α-toxin and phenol-soluble modulins, are also respon-
sible for increased infection severity [33,34]. Regardless, the
selection of antibiotics in the treatment of MRSA pneumonia
characterized by hemoptysis, leukopenia, high fever, and a
cavitary picture on chest radiograph [35] as well as other
necrotizing infections may be of clinical significance.
Secretory toxin production is likely enhanced by beta-lactams
such as nafcillin or oxacillin, maintained by vancomycin, and
inhibited, even at sub-inhibitory concentrations, by protein-
synthesis inhibitors, including clindamycin, rifampin, and
linezolid [36,37]. As such, it may be reasonable to combine
these toxin-suppressing agents with beta-lactams or vanco-
mycin in severe MRSA infections.
Antimicrobial agents for MRSA
Timely provision of appropriate antimicrobial coverage in an
initial anti-infective treatment regimen results in optimal
outcomes for bacterial and fungal infections [29,38,39]. This
is also true for MRSA infections where it has been shown that
antimicrobial regimens not targeting MRSA when it is the
cause of serious infection (for example, pneumonia, bacter-
emia) results in greater mortality and longer lengths of
hospitalization [29,30]. The following represents the anti-
microbial agents currently available for serious MRSA
infections and those in development (Table 1).
Currently available MRSA agents
Vancomycin
Vancomycin has been considered a first-line therapy for
invasive MRSA infections as a result of a relatively clean
safety profile, durability against resistance development and
the lack of other approved alternatives for many years.
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the availability of alternative agents have led to questioning of
vancomycin’s efficacy in many serious infections. The
possible reasons for vancomycin clinical failure are many and
include poor penetration into certain tissues [40], loss of
accessory gene-regulator function in MRSA [12], and
potentially escalating MICs of MRSA to vancomycin [41]. To
circumvent the possibility of poor outcomes with vancomycin
therapy in MRSA infections with MICs ≥1.5 mcg/ml, consen-
sus guidelines recommend a strategy of optimizing the
vancomycin pharmacokinetic-pharmacodynamic profile such
that trough concentrations of 15 to 20 mcg/ml are achieved
[42,43]. Unfortunately, in MRSA infections where vancomycin
distribution to the site of infection is limited (for example,
lung) it is unlikely that targeted concentrations will be
reached [44]. Furthermore, when higher trough concen-
trations are achieved this may not improve outcome [45,46]
and could in fact increase the likelihood of nephrotoxicity
[46-48]. The key to successful outcomes then falls to
identifying patients at risk for having an MRSA infection with
a vancomycin MIC that is 1.5 mcg/ml or greater and using an
alternative agent. Not surprisingly, recent vancomycin
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Table 1
Antibiotics currently available for the treatment of serious methicillin-resistant S. aureus infections
Volume of  Elimination  Protein 
distribution half-life  binding 
Antibiotic Primary indications Daily dosea (L/kg) (hr) (%) Main toxicity
Vancomycin Pneumonia 30 mg/kg/day 0.2 to 1.25 4 to 6 30 to 55 Nephrotoxicity (higher doses)
Skin/soft tissues Thrombocytopenia
Bacteremia
Linezolid Pneumonia 600 mg q 12 h 0.5 -0 .6 5 31 Myelosuppression (prolonged 
duration generally >2 weeks)
Skin/soft tissues Lactic acidosis
Peripheral and optic 
neuropathy
Serotonin syndrome
Tigecycline Skin/soft tissues 100 mg load 7 to 10 37 to 66 71 to 89 Nausea
Intra-abdominal 50 mg q 12 h Vomiting
Photosensitivity
Daptomycin Bacteremia Bacteremia: 6 mg/kg q 24 h 0.09 8 to 9 92 Muscle toxicity
Skin/soft tissues Skin/soft tissues: 4 mg/kg q 24 h CPK elevation
Quinupristin/ Skin/soft tissues 7.5 mg/kg q 8 h 0.56 to 0 .98 0.54 to 1.14 11 to 78 Phlebitis
dalfopristin (via central vein) Arthralgias and myalgias
Ceftobiproleb Skin/soft tissues 500 mg q 8 h 0.25 to 0.30 3 to 4 16 Allergic reactions
Ceftarolinec Skin/soft tissues 600 mg q 12 h 0.22 to 0.25 2.5 to 3 18 Allergic reactions
Pneumonia
Dalbavancinc Skin/soft tissues 1,000 mg day 1 0.011 147 to 258 93 Nausea
500 mg weekly Vomiting
Oritavancinc Skin/soft tissues 1.5 to 3 mg/kg q 24 h 0.65 to 1.92 195 90 Nausea
Vomiting
Telavancinc Skin/soft tissues 7.5 to 10 mg/kg day 0.1 7 to 9 93 Renal thrombocytopenia
Pneumonia
Iclaprimd Skin/soft tissues 0.8 mg/kg q 12 h 1.15 2.5 to 4.1 93
aDaily dose listed assumes normal kidney and liver function. bNot approved for clinical use in the US. Greater risk of clinical failure in ventilator-
associated pneumonia compared to vancomycin plus ceftazadine. cNot approved for clinical use in the US at the time of writing. dNot approved for
clinical use in the US. Failed to demonstrate non-inferiority against linezolid for treatment of complicated skin and skin structure infection. CPK,
creatine phosphokinase.exposure prior to a suspected or proven MRSA infection,
even in a single dose, is a strong predictor of higher vanco-
mycin MICs [49].
Linezolid
Linezolid is currently approved by the US Food and Drug
Administration for the treatment of complicated skin and skin
structure infections and nosocomial pneumonia caused by
susceptible pathogens, including MRSA. Much debate exists
whether linezolid should be considered the drug of choice for
MRSA pneumonia on the basis of two retrospective analyses
of pooled data from randomized trials comparing linezolid and
vancomycin for nosocomial pneumonia [50,51]. In these
retrospective analyses, linezolid therapy was associated with
increased survival, but one limitation is that vancomycin may
have been dosed inadequately, leading to suboptimal
concentrations. A randomized, double-blind trial is underway
in an effort to either confirm or refute these findings in
hospitalized patients with nosocomial pneumonia due to
MRSA. Linezolid should also be considered for necrotizing
infections, including skin lesions, fasciitis, and pneumonia
caused by CA-MRSA as it has been hypothesized that
antibiotics with the ability to inhibit protein synthesis may
demonstrate efficacy against susceptible toxin-producing
strains [36]. Recent guidelines [52] recommend against the
use of linezolid as empiric therapy for catheter-related blood
stream infections (CRBSIs) as one study [53] comparing
vancomycin and linezolid for empiric therapy of complicated
skin and soft tissue infections and CRBSI found a trend
toward increased mortality in the linezolid group when
performing a Kaplan-meier analysis of the intent-to-treat
population. In the primary analysis of this study, linezolid was
found to be non-inferior to the control group, and a subgroup
analysis of patients with MRSA bacteremia showed improved
outcomes in the linezolid group [53]. Linezolid is
recommended as an alternative agent for CRBSI due to
MRSA in this same guideline [52]. Safety concerns that
sometimes limit the use of this agent include the association
of serotonin toxicity and thrombocytopenia [54].
Tigecycline
Tigecycline is the first drug approved in the class of
glycylcyclines, a derivative of minocycline. A modified side
chain on tigecycline enhances binding to the 30s ribosomal
subunit, inhibiting protein synthesis and bacterial growth
against a broad spectrum of pathogens, including MRSA
[55]. Tigecycline is approved in the United States for the
treatment of complicated MRSA skin and skin structure
infections. The drug is also approved for the treatment of
complicated intra-abdominal infections, but for MSSA only.
Tigecycline has a large volume of distribution, producing high
concentrations in tissues outside of the bloodstream,
including bile, colon, and the lung [56]. As a result of serum
concentrations that rapidly decline after infusion, caution
should be used in patients with proven or suspected
bacteremia.
Daptomycin
Daptomycin is indicated for MRSA-associated complicated
skin and soft-tissue infections and bloodstream infections,
including right-sided endocarditis. Of note, daptomycin
should not be used in the treatment of MRSA pneumonia as
the drug’s activity is inhibited by pulmonary surfactant. As
previously mentioned, vancomycin resistance may impact
daptomycin susceptibility and the development of reduced
daptomycin susceptibility during prolonged treatment of
MRSA infections has been reported [16]; these observations
should be considered while assessing response to treatment
of MRSA infections. As a result of daptomycin’s potential to
cause myopathy, creatine phosphokinase should be
measured at baseline and weekly thereafter.
Quinupristin/dalfopristin
Quinuprisitn/dalfoprisitin is a combination of two strepto-
gramins, quinupristin and dalfopristin (in a ratio of 30:70 w/w),
that inhibit different sites in protein synthesis. Each individual
component demonstrates bacteriostatic activity; however, the
combination is bactericidal against most Gram-positive
organisms. Importantly, while quinupristin/dalfopristin offers
activity against MRSA and vancomycin-resistant Entero-
coccus faecium, it lacks activity against Enterococcus faecalis.
Quinuprisitn/dalfoprisitin has US Food and Drug
Administration approval for serious infections due to vanco-
mycin-resistant enterococci, and for complicated skin and
skin-structure infections. Severe arthralgias and myalgias
occur in up to half of patients and, as a result, patient
tolerability can limit this agent’s utility.
Investigational MRSA agents
Ceftobiprole
Ceftobiprole medocaril is a fifth-generation cephalosporin
prodrug with a broad spectrum of activity. This agent was
designed to maximize binding to PBP2a and yield potent anti-
MRSA activity [57]. Ceftobiprole is also active against
cephalosporin-resistant Streptococcus pneumoniae, ampicillin-
sensitive E. faecalis, and has a Gram-negative spectrum of
activity intermediate between ceftriaxone and cefepime
inclusive of Pseudomonas aeruginosa. Two phase III clinical
trials have been completed with ceftobiprole for complicated
skin and skin structure infections [58,59]. Ceftobiprole was
also compared to a combination of ceftazidime plus linezolid
for treatment of nosocomial pneumonia. Ceftobiprole was
unexpectedly associated with lower cure rates in patients
with ventilator-associated pneumonia, particularly in those
under age 45 and with high creatinine clearance [60].
Ceftaroline
Ceftaroline fosamil is also a fifth-generation cephalosporin
prodrug, so named due to its spectrum of activity against a
broad range of Gram-positive and Gram-negative bacteria.
Ceftaroline is active against MRSA due to its enhanced
binding to PBP2a compared to other β-lactam antibiotics
[61]. The drug is also active against penicillin- and
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cocci, E. faecalis (variable activity), but has little to no activity
against vancomycin-resistant E. faecium. Against relevant
Gram-negative pathogens, ceftaroline has broad-spectrum
activity similar to that of ceftriaxone and the drug is expected
to be inactive against Pseudomonas and Acinetobacter spp.
[61]. Phase III studies have been conducted for complicated
skin and skin structure infections and community-acquired
pneumonia, the results of which are pending. Adverse effects
in all ceftaroline studies to date have been minor, and include
headache, nausea, insomnia, and abnormal body odor [62].
Dalbavancin
Dalbavancin is an investigational lipoglycopeptide with a
bactericidal mechanism of action similar to other glycopep-
tides in that it complexes with the D-alanyl-D-alanine (D-Ala-
D-Ala) terminal of peptidoglycan and inhibits transglyco-
sylation and transpeptidation. Like teicoplanin, dalbavancin
possesses a lipophilic side chain that leads to both high
protein binding and an extended half-life, which allows for a
unique once-weekly dosing of the drug [63]. Dalbavancin is
more potent than vancomycin against staphylococci, and is
highly active against both MSSA and MRSA. Dalbavancin is
also active against VISA, although MIC90 ranges are higher at
1 to 2 mcg/ml. However, dalbavancin is not active against
enterococci with the VanA phenotype [64]. Clinical data for
dalbavancin include phase II and III trials in both uncom-
plicated and complicated skin and skin structure infections,
and catheter-related bloodstream infections. Dalbavancin has
been well-tolerated throughout clinical trials, with the most
commonly seen adverse effects being fever, headache, and
nausea.
Oritavancin
Oritavancin, another investigational glycopeptide, contains
novel structural modifications that allow it to dimerize and
anchor itself in the bacterial membrane. These modifications
also confer an enhanced spectrum of activity over traditional
glycopeptide antibiotics [65]. Ortivancin has similar in vitro
activity as vancomycin against staphylococci and is equi-
potent against both MSSA and MRSA. It also has activity
against VISA and VRSA, but MICs are increased to 1 mg/L
and 0.5 mg/L, respectively [66]. Oritivancin is active against
enterococci, including vancomycin-resistant enterococci;
however, MICs are significantly higher for vancomycin-
resistant enterococci versus vancomycin-sensitive strains.
Telavancin
Telavancin is an investigational glycopeptide derivative of
vancomycin. Like oritavancin, telavancin has the ability to
anchor itself in the bacterial membrane, which disrupts
polymerization and crosslinking of peptidoglycan. Telavancin
also interferes with the normal function of the bacterial
membrane, leading to a decrease in the barrier function of the
membrane. This dual mechanism helps to explain its high
potency and rapid bactericidal activity [60]. Telavancin is
bactericidal against staphylococci, including MRSA, VISA,
and VRSA, with MIC90 ranges of 0.25 to 1, 0.5 to 2, and 2 to
4 mg/L, respectively [67]. Telavancin, like oritavancin, is
potent against both penicillin-susceptible and -resistant
strains of S. pneumoniae. Telavancin is also active against
vancomycin-susceptible  E. faecium and  E. faecalis. Two
identical skin and skin structure trials, ATLAS I and II,
compared telavancin 10 mg/kg/day to vancomycin 1 g every
12 hours and found telavancin to be non-inferior to vanco-
mycin [63]. Telavancin has also been studied in hospital-
acquired pneumonia.
Iclaprim
Iclaprim (formerly AR-100 and Ro 48-2622) is an investi-
gational intravenous diaminopyrimidine antibacterial agent
that, like trimethoprim, selectively inhibits dihydrofolate
reductase of both Gram-positive and Gram-negative bacteria
and exerts bactericidal effects [68]. Iclaprim is active against
MSSA, community- and nosocomial-MRSA, VISA, VRSA,
groups A and B streptococci, and pneumococci, and is
variably active against enterococci [69,70]. Iclaprim appears
to have similar Gram-negative activity to that of trimethoprim,
including activity against Escherichia coli,  Klebsiella
pneumoniae, Enterobacter, Citrobacter freundii, and Proteus
vulgaris. Iclaprim also appears to have activity against the
atypical respiratory pathogens Legionella  and  Chlamydia
pneumoniae, but is not active against P. aeruginosa or
anaerobes [69].
Conclusion
MRSA will continue to be an important infection in the ICU
setting for the foreseeable future. Clinicians should be aware
of the changing virulence patterns and antimicrobial
susceptibility patterns of MRSA in their local areas. This
information should be used to develop prevention and
treatment strategies aimed at minimizing patient morbidity
and healthcare costs related to MRSA infections.
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